

UNIVERSITY OF BRESCIA, ANTARES VISION GROUP AND DOMPE' FARMACEUTICI: 2,000 SQ.M. in the UNIVERSITY CAMPUS TO DEVELOP THE FUTURE'S HOSPITALS AND HEALTHCARE

A research and innovation infrastructure for the development of Digital Healthcare, Biopharma, Artificial Intelligence, and Big Data will be created with the contribution of Next Generation EU.

Brescia, 29 June 2022 - The **University of Brescia** has signed an agreement with **Antares Vision Group**, an Italian product and chain quality traceability and control multinational, and with **Dompè farmaceutici S.p.A.**, a leading Italian company in the bio-pharmaceutical sector, for the development of an integrated system of infrastructures that will expand by approximately 2,000 sq.m. the **Technological Multisector Service Centre** in the building owned by the University inside the North university campus.

The project, the result of a public and private partnership which has collected EUR 19.5 million in funds, known as **L.I.G.H.T. – Lifescience Innovation Good Healthcare Technology** – will develop healthcare technologies pursuing three important goals:

- **AI and Big Data Main Hub:** large-scale analysis, storage, and construction of platforms for sharing the data collected, creation and update of websites.
- **Digital Health Care Hub:** development of a smart hospital with geo-referenced rooms and beds equipped with sensors and communication systems for continuous monitoring, development of telemedicine digital technologies, and for improved remote control of the patient, creation of drug tracking solutions that aim to protect the quality and integrity of the medicinal products themselves and reduce administration errors or counterfeiting.
- **AI Biopharma Hub:** development of a fully integrated structure based on artificial intelligence that can design, synthesise, and define the activity of new drugs and bio-pharmaceuticals, in collaboration with the **EXSCALATE** platform of **Dompè farmaceutici S.p.a.**

The **L.I.G.H.T.** infrastructural project is consistent with the 17 **Sustainable Development Goals of the 2030 Agenda** signed by the members of the UN and focuses on the **Green New Deal**:

- it is in line with goal no.3 **“Good health and well-being”** as it aims to develop new technological solutions for healthy and ill patients, and to design a smart hospital prototype.
- it complies with the principles of goal no.5 **“Gender equality”** as all governing bodies of the infrastructure will be designed in conformity with the gender equality principles.
- it aims to reach goal no.9 **“Industry, innovation and infrastructure”** as its purpose is to design an infrastructure where public and private entities exchange ideas and experiences for a new open innovation system, with three targets:

a) increasing the contact and meeting points between basic research and industrial research to create new solutions for health and well-being; b) set up new innovative undertakings; c) revise the curricula for the training of new professional figures in the medical field and in the field of new technologies for health.

*“The main goal of the initiative is to strengthen the collaboration between the University of Brescia and private companies aiming at a more in-depth integration of basic research skills with skills in industrial and experimental research”, states the **Chancellor, Prof. Maurizio Tira**. “Moreover, the project will have a significant impact on knowledge that can be applied to the digital transition of healthcare providers”.*

*“Technological Innovation Infrastructures - adds **Prof. Marina Pizzi, Vice Chancellor for research** - represent vital initiatives for Italian research that must prove that they are able to integrate to an increasing degree in the years to come, following the PNRR [Italy’s recovery and resilience plan], with significant effects for the entire national research system and its technological transfer into products that citizens can use”.*

*“We are proud to partner with the University of Brescia in this project that, thanks to its concreteness, we believe can trigger a virtuous circle of contacts and partnerships among various entities in our country. In the words of Emidio Zorzella, Chairman and Co-CEO of Antares Vision Group, “**We have always believed in research, in innovation, and in a multidisciplinary approach as a driver for growth, transformation, and sustainability**”.*

*“The collaboration between public and private entities and open innovation have, for some time, been one of the driving forces of the research carried out by Dompé farmaceutici - commented **Marcello Allegretti, Chief Scientific Officer** of the Milan-based company - I believe that our EXSCALATE platform, which is based on artificial intelligence and supercomputing, can make a significant contribution towards the success of the initiative, producing new knowledge, accelerating drug discovery times, and consolidating the scientific network with new partners”.*

ANTARES VISION GROUP

Antares Vision Group is a technological partner of excellence in digitalisation and innovation for undertakings and institutions, to guarantee the safety of products and people, the competitiveness of businesses and the protection of the planet.

It provides a unique, comprehensive range of technologies to guarantee product quality (inspection systems and machines) and product traceability along the supply chain (from raw materials to production, from distribution to the consumer) by leveraging the integrated management of production and supply chain data, as well as applying artificial intelligence and blockchain technology. Antares Vision Group is active in the life sciences (pharmaceutical, biomedical devices, and hospitals), beverage & food and cosmetics sectors, and has the potential to expand to other sectors.

www.antaressvision.com and on www.antaressvisiongroup.com.

For further information

Antares Vision PR Specialist

raffaella.mora@partner.antaressvision.com

+39 349 0709470

DOMPE' FARMACEUTICI

Dompé farmaceutici is a bio-pharmaceutical company that has committed to scientific research for over 130 years. Today, Dompé has more than 800 employees around the world, a commercial site in the United States, in San Francisco’s Bay Area, and a research and development facility in Boston. The company has adopted an open innovation approach that can count on a network of over 300

centres and universities around the globe, and on EXSCALATE, one of the most powerful drug design and drug repositioning platforms in the world, thanks to the use of supercomputing structures and artificial intelligence software (www.dompe.com)

For further information

Dompé Corporate Communications

pacc@dompe.com

+39 02 583 831

University of Brescia Press Office

comunicazione@unibs.it

+ 39 030 2988231

Antares Vision Press Office

federica.menichino@axel-comm.it

+39 3496976982

Dompé Corporate Communications

pacc@dompe.com

+39 02 583 831